Asston Pharmaceuticals opened lower at ₹154.00, compared with its previous close of ₹155.25. In the last trading session on 12 Nov 2026, the stock traded between ₹151.00 and ₹161.00, with an average traded price of ₹157.80. It showed an upward intraday trend.
An investment of ₹10,000 made 2 years ago in Asston Pharmaceuticals is now worth
₹ 12,873.00
Giving a profit of
₹ 2,873.00 (28.73%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+5.60 (+3.61%)
Day High
₹161.00
Day Low
₹151.00
Day Open
₹154.00
Prev Close
₹155.25
Volume
17,000
Value Traded
₹0.27 Cr
1W Return
16.56%
1M Return
69.76%
3M Return
100.44%
6M Return
95.08%
1Y Return
112.76%
Market Cap (₹ Cr.)
176
PE Ratio
43.90
PB Ratio
2.55
Dividend Yield
-
ROE
9.95%
ROCE
12.25%
Book Value (₹)
60.96
Face Value (₹)
10.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
16.56%
6 Weeks
-
1 Month
69.76%
3 Months
100.44%
9 Months
96.64%
No data available.
Asston Pharma H1FY27 Results: Net profit falls 3% YoY to ₹327 lakh
Net profit declined 3% YoY to ₹327.37 lakh in H1FY27. Revenue from operations fell 1% YoY to ₹1,526.58 lakh. Cash and cash equivalents surged to ₹1,598.63 lakh from ₹129.08 lakh. EPS dropped to ₹3.70 from ₹9.35 in the same period last year. Preferential allotment raised ₹27.72 crore, boosting equity capital.
TodayAsston Pharmaceuticals shifts registered office to Nerul effective Oct 15
Registered office shifted to Nerul, Navi Mumbai effective October 15, 2026. New location is within the same city and Registrar of Companies jurisdiction. Board approved the move during a meeting held on October 13, 2026.
1mo agoAsston Pharmaceuticals AGM sees 100% approval for all resolutions
All six resolutions at Asston Pharmaceuticals' 7th AGM passed with 100% votes in favour. Promoter group abstained from voting on director remuneration hikes, leaving public shareholders to decide. M/s Panchal S K & Associates ratified as statutory auditors following board appointment. Total valid votes for financial statement adoption stood at 4,597,509.
1mo agoAsston Pharmaceuticals sets September 29 date for 7th AGM, approves pay hikes
Asston Pharmaceuticals schedules 7th AGM for September 29, 2026. Managing Director and CEO pay doubled to ₹6.5 lakh per month. Non-executive director salary raised to ₹2.5 lakh per month. M/s Panchal S K & Associates appointed as statutory auditor for five years.
2mo agoAsston Pharma approves preferential allotment of 24 lakh shares at ₹115
Asston Pharmaceuticals approved preferential allotment of 24,10,431 shares at ₹115 each. Paid-up equity capital increases to ₹10.92 crore comprising 1,09,22,791 shares. Top two investors account for over 85% of the total allotment. Fifteen public category investors participated in the issuance.
2mo agoPrakruti R Pali raises Asston Pharma stake to 9.03% via open market buy
Prakruti R Pali raised stake in Asston Pharma to 9.03%. Acquired 1,51,000 shares worth 1.77% on September 1, 2026. Total holding now stands at 7,69,000 equity shares. Transaction executed via open market mechanism.
2mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹434.55 | +0.78% | ₹1,51,313.06 | 52.00 | +51.38% | |
| ₹7,041.50 | +1.71% | ₹1,49,215.28 | 49.30 | +43.00% | |
| ₹31,940.00 | +11.89% | ₹1,42,364.13 | 110.60 | +45.06% | |
| ₹3,721.20 | +1.37% | ₹1,32,519.56 | 39.40 | +21.74% | |
| ₹834.60 | +1.56% | ₹1,31,487.06 | 94.70 | +12.81% | |
| ₹3,195.00 | +5.18% | ₹1,13,780.50 | 72.60 | -2.70% | |
| ₹4,425.50 | +5.37% | ₹1,13,313.39 | 74.80 | +41.50% | |
| ₹2,622.00 | +1.94% | ₹75,422.18 | 19.00 | -21.90% | |
| ₹14,453.00 | +0.66% | ₹60,518.09 | 43.70 | +60.95% | |
| ₹38.54 | -0.82% | ₹52,975.49 | 23.40 | -34.10% | |
| ₹902.20 | +0.80% | ₹40,955.51 | 22.70 | -15.17% | |
| ₹2,742.70 | +0.75% | ₹32,681.00 | 55.50 | -10.40% |
An investment of ₹10,000 made 2 years ago in Asston Pharmaceuticals is now worth
₹ 12,873.00
Giving a profit of
₹ 2,873.00 (28.73%)
Note: Past profits do not guarantee future returns.
